Tennstedt Pierre, Bölch Charlotte, Strobel Gundula, Minner Sarah, Burkhardt Lia, Grob Tobias, Masser Sawinee, Sauter Guido, Schlomm Thorsten, Simon Ronald
Martini-Clinic, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Pathology, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Int J Oncol. 2014 Feb;44(2):609-15. doi: 10.3892/ijo.2013.2200. Epub 2013 Nov 29.
Tumor protein D52 (TPD52) is located at chromosome 8q21, a region that is frequently gained or amplified in multiple human cancer types. TPD52 has been suggested as a potential target for new anticancer therapies. In order to analyze TPD52 expression in the most prevalent human cancer types, we employed quantitative PCR to measure TPD52 mRNA levels in formalin-fixed tissue samples from more than 900 cancer tissues obtained from 29 different human cancer types. TPD52 was expressed at varying levels in all tested normal tissues, including skin, lymph node, lung, oral mucosa, breast, endometrium, ovary, vulva, myometrium, liver, pancreas, stomach, kidney, prostate, testis, urinary bladder, thyroid gland, brain, muscle and fat tissue. TPD52 was upregulated in 18/29 (62%) tested cancer types. Strongest expression was found in non-seminoma (56-fold overexpression compared to corresponding normal tissue), seminoma (42-fold), ductal (28-fold) and lobular breast cancer (14-fold). In these tumor types, TPD52 upregulation was found in the vast majority (>80%) of tested samples. Downregulation was found in 11 (38%) tumor types, most strongly in papillary renal cell cancer (-8-fold), leiomyosarcoma (-6-fold), clear cell renal cell cancer (-5-fold), liposarcoma (-5-fold) and lung cancer (-4-fold). These results demonstrate that TPD52 is frequently and strongly upregulated in many human cancer types, which may represent candidate tumor types for potential anti-TPD52 therapies.
肿瘤蛋白D52（TPD52）位于8号染色体q21区，该区域在多种人类癌症类型中经常出现获得性改变或扩增。TPD52已被认为是新型抗癌疗法的潜在靶点。为了分析TPD52在最常见的人类癌症类型中的表达情况，我们采用定量PCR检测了来自29种不同人类癌症类型的900多个癌组织的福尔马林固定组织样本中TPD52的mRNA水平。TPD52在所有测试的正常组织中均有不同程度的表达，包括皮肤、淋巴结、肺、口腔黏膜、乳腺、子宫内膜、卵巢、外阴、子宫肌层、肝脏、胰腺、胃、肾脏、前列腺、睾丸、膀胱、甲状腺、脑、肌肉和脂肪组织。在29种测试的癌症类型中，有18种（62%）TPD52表达上调。在非精原细胞瘤（与相应正常组织相比过表达56倍）、精原细胞瘤（42倍）、导管性（28倍）和小叶性乳腺癌（14倍）中发现最强的表达。在这些肿瘤类型中，绝大多数（>80%）测试样本中发现TPD52上调。在11种（38%）肿瘤类型中发现下调，最明显的是乳头状肾细胞癌（-8倍）、平滑肌肉瘤（-6倍）、透明细胞肾细胞癌（-5倍）、脂肪肉瘤（-5倍）和肺癌（-4倍）。这些结果表明，TPD52在许多人类癌症类型中经常且强烈上调，这可能代表了潜在抗TPD52疗法的候选肿瘤类型。
